Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - ethinylestradiol; drospirenone - film-coated tablet - 0.02 mg/ 3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - drospirenone; ethinylestradiol - film-coated tablet - 0.03 mg/3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - drospirenone, ethinylestradiol - film coated tablet - 0.03 / 3 milligram - progestogens and estrogens, fixed combinations

Uganda - English - National Drug Authority

nectar lifesciences ltd - cefixime - oral solid ordinary film-coated tablets - 100mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains abiraterone 250,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - tablet - see ingredients - each tablet contains raloxifene hydrochloride 60,0 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

nectar lifesciences limited, india - cefixime - tablets - 400

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

nectar lifesciences limited, india - cefixime 200 - tablets - 400 mg

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. however, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. jolivette ® tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: - known or suspected pregnancy - known or suspected carcinoma of the breast - undiagnosed abnormal genital bleeding - hypersensitivity to any component of this product - benign or malignant liver tumors - acute liver disease 1. open the compact. place the blister into the compact, with the tablets facing up, so that the v notch in the blister card matches up with the v-shaped post at the top of the compact. press down firmly on each edge of t